You are here

FDA Reports Recent Case of Brain Infection With Gilenya

Patients with weak immunity most at risk (August 29)
This is the first case of progressive multifocal leukoencephalopathy (PML) reported following the administration of fingolimod to a patient who had not previously received natalizumab (Tysabri, Biogen Idec), a medication for MS that is associated with a higher risk of PML. Fingolimod is used to treat relapsing forms of MS, which affects the brain and spinal cord.

PML is caused by the John Cunningham (JC) virus, which damages myelin, the fatty covering of the brain. PML usually results in death or severe disability and mostly affects those with weakened immune systems.

Patients should not discontinue fingolimod therapy without first consulting their health care professional. Novartis stated that the firm does not believe fingolimod was responsible for PML in this case. The patient was taking other drugs besides fingolimod, Novartis and the FDA explained.

Source: FDA

Recent Headlines

Attacks Cancerous Cells, Leaves Healthy Tissues Alone
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Moderates Pre-diabetes Progression, Reduces Cholesterol Levels
​NCI Study: Radioactive Iodine Associated With Solid Tumors
Old Chemo Drug at High Doses Goads Immune System to Fight Lymphoma
Findings May Explain Apparent Opioid-Seeking Behavior, Opioid Overuse